FDA seeks patient input for public meeting on IPF

FDA is asking patients with idiopathic pulmonary fibrosis (IPF) for input on therapies to treat the disease as part of a public meeting on Sept. 26. The meeting is part of FDA's Patient-Focused Drug Development initiative, under which FDA is holding public meetings for 20 diseases to discuss the impact of the disease, the measures of benefit that matter most to patients and the adequacy of existing treatment options. The agency has already held meetings on chronic fatigue syndrome (CFS), HIV, lung cancer, narcolepsy, sickle cell disease, fibromyalgia, pulmonary arterial hypertension (PAH) and the neurological manifestations of inborn errors of metabolism. ...